Document is current
Any future updates will be listed below
-
Authors
Wu, Chunjing
Spector, Sydney A.
Theodoropoulos, George
Nguyen, Dan J. M.
Kim, Emily Y.
Garcia, Ashley
Savaraj, Niramol
Lim, Diane C.
Paul, Ankita
Feun, Lynn G.
Bickerdike, Michael
Wangpaichitr, Medhi https://orcid.org/0000-0002-7338-2041
-
Funding
Funding for this research was provided by:
Sylvester Comprehensive Cancer Center, University of Miami Health Systems (1P30CA240139, 1P30CA240139)
U.S. Department of Veterans Affairs (1I01BX004371)
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 10 May 2023
First Online: 24 May 2023
Declarations
:
: The animal study was reviewed and approved by The Institutional Animal Care and Use Committee (IACUC) at the Miami VA Healthcare System. (Animal Welfare Assurance Number: A3739–01).MB reports that AT-0174 (patent no.US20210145839A1) was granted and provided for use by Antido Therapeutics and Miami VA Healthcare System.MB and MW report provisional patent no. US63/316740 entitled “Dual inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in Therapy”.
: MB is employed by Antido Therapeutics (Australia) Pty Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
